Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

BACKGROUND AIMS The Quantum® Cell Expansion System (Quantum; Terumo BCT, Inc, Lakewood, CO, USA) is a novel hollow fiber-based device that automates and closes the cell culture process, reducing labor intensive tasks such as manual cell culture feeding and harvesting. The manual cell selection and expansion processes for the production of clinical-scale quantities of bone marrow-derived human mesenchymal stromal cells (BM-hMSCs) have been successfully translated onto the Quantum platform previously. The formerly static, manual, in vitro process performed primarily on tissue culture polystyrene substrates may raise the question of whether BM-hMSCs cultured on a hollow fiber platform yields comparable cell quality. METHODS A rigorous battery of assays was used to determine the genetic stability of BM-hMSCs selected and produced with the Quantum. In this study, genetic stability was determined by assessing spectral karyotype, micronucleus formation and tumorigenicity to resolve chromosomal aberrations in the stem cell population. Cell phenotype, adherent growth kinetics and tri-lineage differentiation were also evaluated. HMSC bone marrow aspirates, obtained from three approved donors, were expanded in parallel using T225 culture flasks and the Quantum. RESULTS BM-hMSCs harvested from the Quantum demonstrated immunophenotype, morphology and tri-lineage differentiation capacity characteristics consistent with the International Society of Cell Therapy standard for hMSCs. Cell populations showed no malignant neoplastic formation in athymic mice 60 days post-transplant, no clonal chromosomal aberrations were observed and no DNA damage was found as measured by micronucleus formation. CONCLUSIONS Quantum-produced BM-hMSCs are of comparable quality and demonstrate analogous genetic stability to BM-hMSCs cultured on tissue culture polystyrene substrates.

[1]  M. Kassem,et al.  Selenium Supplementation Restores the Antioxidative Capacity and Prevents Cell Damage in Bone Marrow Stromal Cells In Vitro , 2006, Stem cells.

[2]  D. Huso,et al.  Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. , 2005, Cytotherapy.

[3]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[4]  D. Euhus,et al.  Tumor measurement in the nude mouse , 1986, Journal of surgical oncology.

[5]  J. Rygaard,et al.  The Nude Mouse vs. The Hypothesis of Immunological Surveillance , 1976, Transplantation reviews.

[6]  J. Tolar,et al.  Mesenchymal stromal cells from donors varying widely in age are of equal cellular fitness after in vitro expansion under hypoxic conditions. , 2010, Cytotherapy.

[7]  Stephen D Dertinger,et al.  In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. , 2007, Mutation research.

[8]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[9]  H. Mayani,et al.  Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. , 2009, Cytotherapy.

[10]  J. Huret Atlas of Genetics and Cytogenetics in Oncology and Haematology , 2014 .

[11]  Y. Miller,et al.  Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. , 2007, American journal of respiratory and critical care medicine.

[12]  L. Rosenberg,et al.  Ex Vivo Expansion of Human Mesenchymal Stem Cells in Defined Serum-Free Media , 2012, Stem cells international.

[13]  Baojin Fu,et al.  Accumulated Chromosomal Instability in Murine Bone Marrow Mesenchymal Stem Cells Leads to Malignant Transformation , 2006, Stem cells.

[14]  D. Gisselsson,et al.  Abnormal nuclear shape in solid tumors reflects mitotic instability. , 2001, The American journal of pathology.

[15]  J. Rygaard,et al.  Heterotransplantation of a human malignant tumour to "Nude" mice. , 2009, Acta pathologica et microbiologica Scandinavica.

[16]  P. Rao,et al.  Genetically transforming human mesenchymal stem cells to sarcomas , 2009, Cancer.

[17]  G. Verdonk,et al.  Variations in the stromal cell population of human bone marrow during aging , 1981, Mechanisms of Ageing and Development.

[18]  Alan W. Stitt,et al.  Endothelial Progenitors as Tools to Study Vascular Disease , 2012, Stem cells international.

[19]  A. Friedenstein,et al.  HETEROTOPIC TRANSPLANTS OF BONE MARROW , 1968 .

[20]  T. Jensen,et al.  Adult human mesenchymal stem cell as a target for neoplastic transformation , 2004, Oncogene.

[21]  J. Savage Micronuclei: pitfalls and problems , 2011 .

[22]  S. Kang,et al.  Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. , 2011, Stem cells and development.

[23]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[24]  W. R. Bishop,et al.  SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53 , 2010, The Journal of Biological Chemistry.

[25]  Stephen D Dertinger,et al.  Interlaboratory evaluation of a flow cytometric, high content in vitro micronucleus assay. , 2008, Mutation research.

[26]  M. Kirsch‐Volders,et al.  Chromosomal changes: induction, detection methods and applicability in human biomonitoring. , 2006, Biochimie.

[27]  F. Mitelman International standing committee on human cytogenetic nomenclature , 1996 .

[28]  J. Loring,et al.  Establishing Standards for the Characterization of Human Embryonic Stem Cell Lines , 2006, Stem cells.

[29]  Ludwika Kreja,et al.  GMP-Compliant Isolation and Expansion of Bone Marrow-Derived MSCs in the Closed, Automated Device Quantum Cell Expansion System , 2013, Cell transplantation.

[30]  K. Petrakova,et al.  [Osteogenesis in transplants of bone marrow cells]. , 1969, Arkhiv anatomii, gistologii i embriologii.

[31]  M. Pittenger,et al.  Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.

[32]  A. Giordano,et al.  From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells , 2007, Journal of cellular physiology.

[33]  John Nicolette,et al.  Flow cytometric analysis of micronuclei in mammalian cell cultures: past, present and future. , 2011, Mutagenesis.

[34]  M. Fenech,et al.  Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. , 2011, Mutagenesis.

[35]  Y. Rumpler,et al.  International Standing Committee on Human Cytogenetic Nomenclature , 1976 .

[36]  A. Friedenstein,et al.  Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. , 1968, Transplantation.

[37]  E. Blomme,et al.  In vitro micronucleus screening of pharmaceutical candidates by flow cytometry in Chinese hamster V79 cells , 2011, Environmental and molecular mutagenesis.

[38]  A. Friedenstein,et al.  Colony‐forming cells in organ cultures of embryonal liver , 1970, Journal of cellular physiology.